Associated Papers
Natural Polymorphic Variants in the CYP450 Superfamily: A Review of Potential Structural Mechanisms and Functional Consequences.
Prost R et al.
International Journal of Molecular Sciences, 2025
In-silico screening and analysis of missense SNPs in human CYP3A4/5 affecting drug-enzyme interactions of FDA-approved COVID-19 antiviral drugs.
Abdelazim AA et al.
Scientific Reports, 2025
Individualized tacrolimus therapy: Insights from CYP3A5 polymorphisms and intestinal metabolism.
Mishima M et al.
Clinical Case Reports, 2024
Human Cytochrome P450 1, 2, 3 Families as Pharmacogenes with Emphases on Their Antimalarial and Antituberculosis Drugs and Prevalent African Alleles.
Chamboko CR et al.
International Journal of Molecular Sciences, 2023
36834793 (PubMed )
Supplement: ijms-24-03383-s001.zip › ijms-2130595-supplementary.pdf
PharmVar GeneFocus: CYP3A5.
Rodriguez-Antona C et al.
Clinical Pharmacology and Therapeutics, 2022
Comprehensive analysis of important pharmacogenes in Koreans using the DMET™ platform.
Kim B et al.
Translational and Clinical Pharmacology, 2021
Precision Medicine into Clinical Practice: A Web-Based Tool Enables Real-Time Pharmacogenetic Assessment of Tailored Treatments in Psychiatric Disorders.
Zampatti S et al.
Journal of Personalized Medicine, 2021
A novel polymorphism in ABCB1 gene, CYP2B6*6 and sex predict single-dose efavirenz population pharmacokinetics in Ugandans.
Mukonzo JK et al.
British Journal of Clinical Pharmacology, 2009
Pharmacogenomics of CYP3A: considerations for HIV treatment.
Lakhman SS et al.
Pharmacogenomics, 2009
Significance of the minor cytochrome P450 3A isoforms.
Daly AK
Clinical Pharmacokinetics, 2006
Genetic findings and functional studies of human CYP3A5 single nucleotide polymorphisms in different ethnic groups.
Lee SJ et al.
Pharmacogenetics, 2003
Select a paper to view details